PAI

Palo Alto Investors Portfolio holdings

AUM $470M
1-Year Return 2.57%
This Quarter Return
-15.62%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$1.19B
AUM Growth
-$622M
Cap. Flow
-$255M
Cap. Flow %
-21.34%
Top 10 Hldgs %
72.62%
Holding
40
New
3
Increased
3
Reduced
19
Closed
3

Top Buys

1
RVNC
Revance Therapeutics, Inc.
RVNC
+$7.8M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$725K
3
TVTX icon
Travere Therapeutics
TVTX
+$686K
4
URGN icon
UroGen Pharma
URGN
+$437K
5
PBYI icon
Puma Biotechnology
PBYI
+$397K

Top Sells

1
WMGI
Wright Medical Group Inc
WMGI
+$63.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$40.3M
3
UTHR icon
United Therapeutics
UTHR
+$39.1M
4
ALXN
Alexion Pharmaceuticals Inc
ALXN
+$21.2M
5
STAA icon
STAAR Surgical
STAA
+$16.1M

Sector Composition

1 Healthcare 87.96%
Name Market Value Portfolio Weight Shares or Principal Shares
Change % 		Capital Flow
CYTK icon
26
Cytokinetics
CYTK
$6.06B
$1.46M 0.12%
123,686
– –
ALIM
27
DELISTED
Alimera Sciences, Inc.
ALIM
$804K 0.07%
200,919
– –
ZGNX
28
DELISTED
Zogenix, Inc.
ZGNX
$730K 0.06%
29,500
– –
SNDX icon
29
Syndax Pharmaceuticals
SNDX
$1.31B
$725K 0.06%
+66,100
New +$725K
TVTX icon
30
Travere Therapeutics
TVTX
$2.04B
$686K 0.06%
+47,000
New +$686K
ITCI
31
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$575K 0.05%
37,400
– –
VIRX
32
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$482K 0.04%
33,214
– –
URGN icon
33
UroGen Pharma
URGN
$856M
$437K 0.04%
+24,500
New +$437K
MRNS
34
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$254K 0.02%
31,330
– –
NERV icon
35
Minerva Neurosciences
NERV
$15.4M
$219K 0.02%
4,540
– –
ALDX icon
36
Aldeyra Therapeutics
ALDX
$306M
$182K 0.02%
73,500
– –
ACGN
37
DELISTED
Aceragen, Inc. Common Stock
ACGN
$102K 0.01%
4,537
– –
GILD icon
38
Gilead Sciences
GILD
$138B
– –
-39,300
Closed -$2.55M
MLNT
39
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
– –
-10,137
Closed -$5K
SPHS
40
DELISTED
Sophiris Bio, Inc.
SPHS
– –
-247,000
Closed -$91K
1
2